Ganot Ilan 4

What Happened
Ilan Ganot, a director of Solid Biosciences (SLDB), received equity awards on January 29, 2026 — two derivative grants totaling 106,350 shares (70,900 and 35,450, reported at $0). On January 31, 2026 he exercised/converting a derivative for 15,000 shares and the filing also reports a simultaneous disposal of 15,000 shares at $0. All grants and exercises are reported as derivative transactions (options/RSUs) rather than open-market cash purchases or sales.

Key Details

• Transaction dates and amounts:
  • Jan 29, 2026 — Grant/award entries for 70,900 and 35,450 derivative shares (price $0).
  • Jan 31, 2026 — Exercise/conversion of derivative: 15,000 shares acquired; same date shows 15,000 shares disposed at $0.
• Reported consideration: all transactions reported at $0 (awards and the disposal).
• Shares owned after transactions: the filing reports beneficial ownership items that total 118,691 shares (95,255 held individually, 4,042 held jointly, and 19,394 held in a family trust), per the footnotes.
• Notable footnotes:
  • RSUs convert 1-for-1 into common stock (F1).
  • The 2026 option grant vests over four years (25% after 1 year, then monthly thereafter) (F4).
  • The 2026 RSU grant vests over four years (25% each anniversary) (F5).
  • A prior 2025 RSU grant of 60,000 vests over four years (F6).
• Filing timeliness: Form 4 was filed Feb 2, 2026 for transactions in late Jan 2026 — the filing appears timely (no late filing flag).

Context

• The Jan 29 entries are award-type derivative grants (options/RSUs) that generally vest over time per the footnotes; they do not represent immediate open-market purchases.
• The Jan 31 paired acquisition and $0 disposal of 15,000 shares likely reflects a net settlement or internal transfer (e.g., tax withholding or share surrender) rather than an open-market sale; the filing reports the disposition at $0.
• These filings are factual disclosures of insider holdings and grants; they do not state the insider’s motivation.